
        {
            "id": "0017a82d-4f35-4d17-ab5c-4744dc0effdd",

            "code": {
                "code": "34391-3",
                "codeSystem": "2.16.840.1.113883.6.1",
                "displayName": "HUMAN PRESCRIPTION DRUG LABEL"
            },

            "title": "These highlights do not include all the information needed to use ALYMSYS safely and effectively. See full prescribing information for ALYMSYS . ALYMSYS ® (bevacizumab-maly) injection, for intravenous use Initial U.S. Approval: 2022 ALYMSYS (bevacizumab-maly) is biosimilar* to AVASTIN (bevacizumab)",

            "effectiveTime": "20220423",

            "ingredients": [
                
                    {
                        "name": "BEVACIZUMAB",
                        "code": "2S9ZZM9Q9V"
                    },
                    {
                        "name": "TREHALOSE DIHYDRATE",
                        "code": "7YIN7J07X4"
                    },
                    {
                        "name": "POLYSORBATE 20",
                        "code": "7T1F30V5YH"
                    },
                    {
                        "name": "SODIUM PHOSPHATE, DIBASIC, ANHYDROUS",
                        "code": "22ADO53M6F"
                    },
                    {
                        "name": "SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE",
                        "code": "593YOG76RN"
                    },
                    {
                        "name": "WATER",
                        "code": "059QF0KO0R"
                    },
                    {
                        "name": "BEVACIZUMAB",
                        "code": "2S9ZZM9Q9V"
                    },
                    {
                        "name": "TREHALOSE DIHYDRATE",
                        "code": "7YIN7J07X4"
                    },
                    {
                        "name": "POLYSORBATE 20",
                        "code": "7T1F30V5YH"
                    },
                    {
                        "name": "SODIUM PHOSPHATE, DIBASIC, ANHYDROUS",
                        "code": "22ADO53M6F"
                    },
                    {
                        "name": "SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE",
                        "code": "593YOG76RN"
                    },
                    {
                        "name": "WATER",
                        "code": "059QF0KO0R"
                    }
            ],

            "contraindications": [
                
                            "None."
                            
            ],

            "warningsAndPrecautions": [
                
                            ""
                            ,
                            ""
                            ,
                            ""
                            ,
                            "Gastrointestinal Perforations and Fistula:"
                            ,
                            "Discontinue for gastrointestinal perforations, tracheoesophageal fistula, grade 4 fistula, or fistula formation involving any organ (5.1)"
                            ,
                            ""
                            ,
                            ""
                            ,
                            "Surgery and Wound Healing Complications:"
                            ,
                            "In patients who experience wound healing complications during Alymsys treatment, withhold Alymsys until adequate wound healing. Withhold for at least 28 days prior to elective surgery. Do not administer Alymsys for at least 28 days following a major surgery, and until adequate wound healing. The safety of resumption of bevacizumab products after resolution of wound healing complication has not been established. Discontinue for wound healing complication of necrotizing fasciitis. (5.2)"
                            ,
                            ""
                            ,
                            ""
                            ,
                            "Hemorrhage:"
                            ,
                            "Severe or fatal hemorrhages have occurred. Do not administer for recent hemoptysis. Discontinue for Grade 3-4 hemorrhage (5.3)"
                            ,
                            ""
                            ,
                            ""
                            ,
                            "Arterial Thromboembolic Events (ATE):"
                            ,
                            "Discontinue for severe ATE. (5.4)"
                            ,
                            ""
                            ,
                            ""
                            ,
                            "Venous Thromboembolic Events (VTE):"
                            ,
                            "Discontinue for Grade 4 VTE. (5.5)"
                            ,
                            ""
                            ,
                            ""
                            ,
                            "Hypertension:"
                            ,
                            "Monitor blood pressure and treat hypertension. Withhold if not medically controlled; resume once controlled. Discontinue for hypertensive crisis or hypertensive encephalopathy. (5.6)"
                            ,
                            ""
                            ,
                            ""
                            ,
                            "Posterior Reversible Encephalopathy Syndrome (PRES):"
                            ,
                            "Discontinue. (5.7)"
                            ,
                            ""
                            ,
                            ""
                            ,
                            "Renal Injury and Proteinuria:"
                            ,
                            "Monitor urine protein. Discontinue for nephrotic syndrome. Withhold until less than 2 grams of protein in urine. (5.8)"
                            ,
                            ""
                            ,
                            ""
                            ,
                            "Infusion-Related Reactions:"
                            ,
                            "Decrease rate for infusion-related reactions. Discontinue for severe infusion-related reactions and administer medical therapy. (5.9)"
                            ,
                            ""
                            ,
                            ""
                            ,
                            "Embryo-Fetal Toxicity:"
                            ,
                            "May cause fetal harm. Advise females of potential risk to fetus and need for use of effective contraception. (5.10, 8.1, 8.3)"
                            ,
                            ""
                            ,
                            ""
                            ,
                            "Ovarian Failure:"
                            ,
                            "Advise females of the potential risk. (5.11, 8.3)"
                            ,
                            ""
                            ,
                            ""
                            ,
                            "Congestive Heart Failure (CHF):"
                            ,
                            "Discontinue Alymsys in patients who develop CHF. (5.12)"
                            ,
                            ""
                            ,
                            ""
                            ,
                            ""
                            ,
                            "Serious, and sometimes fatal, gastrointestinal perforation occurred at a higher incidence in patients receiving bevacizumab products compared to patients receiving chemotherapy. The incidence ranged from 0.3% to 3% across clinical studies, with the highest incidence in patients with a history of prior pelvic radiation. Perforation can be complicated by intra-abdominal abscess, fistula formation, and the need for diverting ostomies. The majority of perforations occurred within 50 days of the first dose"
                            ,
                            "[see Adverse Reactions (6.1)]"
                            ,
                            "."
                            ,
                            ""
                            ,
                            "Serious fistulae (including, tracheoesophageal, bronchopleural, biliary, vaginal, renal and bladder sites) occurred at a higher incidence in patients receiving bevacizumab products compared to patients receiving chemotherapy. The incidence ranged from < 1% to 1.8% across clinical studies, with the highest incidence in patients with cervical cancer. The majority of fistulae occurred within 6 months of the first dose. Patients who develop a gastrointestinal vaginal fistula may also have a bowel obstruction and require surgical intervention, as well as a diverting ostomy."
                            ,
                            ""
                            ,
                            "Avoid Alymsys in patients with ovarian cancer who have evidence of recto-sigmoid involvement by pelvic examination or bowel involvement on CT scan or clinical symptoms of bowel obstruction. Discontinue in patients who develop gastrointestinal perforation, tracheoesophageal fistula or any Grade 4 fistula. Discontinue in patients with fistula formation involving any internal organ."
                            ,
                            ""
                            ,
                            ""
                            ,
                            "In a controlled clinical study in which bevacizumab was not administered within 28 days of major surgical procedures, the incidence of wound healing complications, including serious and fatal complications, was 15% in patients with mCRC who underwent surgery while receiving bevacizumab and 4% in patients who did not receive bevacizumab. In a controlled clinical study in patients with relapsed or recurrent GBM, the incidence of wound healing events was 5% in patients who received bevacizumab and 0.7% in patients who did not receive bevacizumab"
                            ,
                            "[see Adverse Reactions (6.1)]"
                            ,
                            "."
                            ,
                            ""
                            ,
                            "In patients who experience wound healing complications during Alymsys treatment, withhold Alymsys until adequate wound healing. Withhold for at least 28 days prior to elective surgery. Do not administer for at least 28 days following major surgery and until adequate wound healing. The safety of resumption of bevacizumab products after resolution of wound healing complications has not been established"
                            ,
                            "[see Dosage and Administration (2.8)]"
                            ,
                            "."
                            ,
                            ""
                            ,
                            "Necrotizing fasciitis including fatal cases, has been reported in patients receiving bevacizumab, usually secondary to wound healing complications, gastrointestinal perforation or fistula formation. Discontinue Alymsys in patients who develop necrotizing fasciitis."
                            ,
                            ""
                            ,
                            ""
                            ,
                            "Bevacizumab products can result in two distinct patterns of bleeding: minor hemorrhage, which is most commonly Grade 1 epistaxis, and serious hemorrhage, which in some cases has been fatal. Severe or fatal hemorrhage, including hemoptysis, gastrointestinal bleeding, hematemesis, CNS hemorrhage, epistaxis, and vaginal bleeding, occurred up to 5-fold more frequently in patients receiving bevacizumab compared to patients receiving chemotherapy alone. Across clinical studies, the incidence of Grades 3 to 5 hemorrhagic events ranged from 0.4% to 7% in patients receiving bevacizumab"
                            ,
                            "[see Adverse Reactions (6.1)]"
                            ,
                            "."
                            ,
                            ""
                            ,
                            "Serious or fatal pulmonary hemorrhage occurred in 31% of patients with squamous NSCLC and 4% of patients with non-squamous NSCLC receiving bevacizumab with chemotherapy compared to none of the patients receiving chemotherapy alone."
                            ,
                            ""
                            ,
                            "Do not administer Alymsys to patients with recent history of hemoptysis of 1/2 teaspoon or more of red blood. Discontinue in patients who develop a Grades 3 to 4 hemorrhage."
                            ,
                            ""
                            ,
                            ""
                            ,
                            "Serious, sometimes fatal, arterial thromboembolic events (ATE) including cerebral infarction, transient ischemic attacks, myocardial infarction, and angina, occurred at a higher incidence in patients receiving bevacizumab compared to patients receiving chemotherapy. Across clinical studies, the incidence of Grades 3 - 5 ATE was 5% in patients receiving bevacizumab with chemotherapy compared to ≤2% in patients receiving chemotherapy alone; the highest incidence occurred in patients with GBM. The risk of developing ATE was increased in patients with a history of arterial thromboembolism, diabetes, or >65 years"
                            ,
                            "[see Use in Specific Populations (8.5)]"
                            ,
                            "."
                            ,
                            ""
                            ,
                            "Discontinue in patients who develop a severe ATE. The safety of reinitiating bevacizumab products after an ATE is resolved is not known."
                            ,
                            ""
                            ,
                            ""
                            ,
                            "An increased risk of venous thromboembolic events (VTE) was observed across clinical studies"
                            ,
                            "[see Adverse Reactions (6.1)]"
                            ,
                            ". In Study GOG-0240, Grades 3 to 4 VTE occurred in 11% of patients receiving bevacizumab with chemotherapy compared with 5% of patients receiving chemotherapy alone. In EORTC 26101, the incidence of Grades 3 to 4 VTE was 5% in patients receiving bevacizumab with chemotherapy compared to 2% in patients receiving chemotherapy alone."
                            ,
                            ""
                            ,
                            "Discontinue Alymsys in patients with a Grade 4 VTE, including pulmonary embolism."
                            ,
                            ""
                            ,
                            ""
                            ,
                            "Severe hypertension occurred at a higher incidence in patients receiving bevacizumab products as compared to patients receiving chemotherapy alone. Across clinical studies, the incidence of Grades 3 - 4 hypertension ranged from 5% to 18%."
                            ,
                            ""
                            ,
                            "Monitor blood pressure every two to three weeks during treatment with Alymsys. Treat with appropriate anti-hypertensive therapy and monitor blood pressure regularly. Continue to monitor blood pressure at regular intervals in patients with Alymsys -induced or -exacerbated hypertension after discontinuing Alymsys. Withhold Alymsys in patients with severe hypertension that is not controlled with medical management; resume once controlled with medical management. Discontinue in patients who develop hypertensive crisis or hypertensive encephalopathy."
                            ,
                            ""
                            ,
                            ""
                            ,
                            "Posterior reversible encephalopathy syndrome (PRES) was reported in <0.5% of patients across clinical studies. The onset of symptoms occurred from 16 hours to 1 year after the first dose. PRES is a neurological disorder which can present with headache, seizure, lethargy, confusion, blindness and other visual and neurologic disturbances. Mild to severe hypertension may be present. Magnetic resonance imaging is necessary to confirm the diagnosis of PRES."
                            ,
                            ""
                            ,
                            "Discontinue Alymsys in patients who develop PRES. Symptoms usually resolve or improve within days after discontinuing bevacizumab products, although some patients have experienced ongoing neurologic sequelae. The safety of reinitiating bevacizumab products in patients who developed PRES is not known."
                            ,
                            ""
                            ,
                            ""
                            ,
                            "The incidence and severity of proteinuria was higher in patients receiving bevacizumab as compared to patients receiving chemotherapy. Grade 3 (defined as urine dipstick 4+ or > 3.5 grams of protein per 24 hours) to Grade 4 (defined as nephrotic syndrome) ranged from 0.7% to 7% in clinical studies. The overall incidence of proteinuria (all grades) was only adequately assessed in Study BO17705, in which the incidence was 20%. Median onset of proteinuria was 5.6 months (15 days to 37 months) after initiating bevacizumab. Median time to resolution was 6.1 months (95% CI: 2.8, 11.3). Proteinuria did not resolve in 40% of patients after median follow-up of 11.2 months and required discontinuation of bevacizumab in 30% of the patients who developed proteinuria"
                            ,
                            "[see Adverse Reactions (6.1)]"
                            ,
                            "."
                            ,
                            ""
                            ,
                            "In an exploratory, pooled analysis of patients from seven randomized clinical studies, 5% of patients receiving bevacizumab with chemotherapy experienced Grades 2 - 4 (defined as urine dipstick 2+ or greater or > 1 gram of protein per 24 hours or nephrotic syndrome) proteinuria. Grades 2 to 4 proteinuria resolved in 74% of patients. Bevacizumab was reinitiated in 42% of patients. Of the 113 patients who reinitiated bevacizumab, 48% experienced a second episode of Grades 2 to 4 proteinuria."
                            ,
                            ""
                            ,
                            "Nephrotic syndrome occurred in <1% of patients receiving bevacizumab across clinical studies, in some instances with fatal outcome. In a published case series, kidney biopsy of 6 patients with proteinuria showed findings consistent with thrombotic microangiopathy. Results of a retrospective analysis of 5,805 patients who received bevacizumab with chemotherapy and 3,713 patients who received chemotherapy alone, showed higher rates of elevated serum creatinine levels (between 1.5 to 1.9 times baseline levels) in patients who received bevacizumab. Serum creatinine levels did not return to baseline in approximately one-third of patients who received bevacizumab."
                            ,
                            ""
                            ,
                            "Monitor proteinuria by dipstick urine analysis for the development or worsening of proteinuria with serial urinalyses during Alymsys therapy. Patients with a 2+ or greater urine dipstick reading should undergo further assessment with a 24-hour urine collection. Withhold for proteinuria greater than or equal to 2 grams per 24 hours and resume when less than 2 grams per 24 hours. Discontinue in patients who develop nephrotic syndrome."
                            ,
                            ""
                            ,
                            "Data from a postmarketing safety study showed poor correlation between UPCR (Urine Protein/Creatinine Ratio) and 24-hour urine protein [Pearson Correlation 0.39 (95% CI: 0.17, 0.57)]."
                            ,
                            ""
                            ,
                            ""
                            ,
                            "Infusion-related reactions reported across clinical studies and postmarketing experience include hypertension, hypertensive crises associated with neurologic signs and symptoms, wheezing, oxygen desaturation, Grade 3 hypersensitivity, chest pain, headaches, rigors, and diaphoresis. In clinical studies, infusion-related reactions with the first dose occurred in <3% of patients and severe reactions occurred in 0.4% of patients."
                            ,
                            ""
                            ,
                            "Decrease the rate of infusion for mild, clinically insignificant infusion-related reactions. Interrupt the infusion in patients with clinically significant infusion-related reactions and consider resuming at a slower rate following resolution. Discontinue in patients who develop a severe infusion-related reaction and administer appropriate medical therapy (e.g., epinephrine, corticosteroids, intravenous antihistamines, bronchodilators and/or oxygen)."
                            ,
                            ""
                            ,
                            ""
                            ,
                            "Based on its mechanism of action and findings from animal studies, bevacizumab products may cause fetal harm when administered to pregnant women. Congenital malformations were observed with the administration of bevacizumab to pregnant rabbits during organogenesis every 3 days at a dose as low as a clinical dose of 10 mg/kg. Furthermore, animal models link angiogenesis and VEGF and VEGFR2 to critical aspects of female reproduction, embryo-fetal development, and postnatal development. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with Alymsys and for 6 months after the last dose"
                            ,
                            "[see Use in Specific Populations (8.1, 8.3)]"
                            ,
                            "."
                            ,
                            ""
                            ,
                            ""
                            ,
                            "The incidence of ovarian failure was 34% vs. 2% in premenopausal women receiving bevacizumab with chemotherapy as compared to those receiving chemotherapy alone for adjuvant treatment of a solid tumor. After discontinuing bevacizumab, recovery of ovarian function at all time points during the post-treatment period was demonstrated in 22% of women receiving bevacizumab. Recovery of ovarian function is defined as resumption of menses, a positive serum β-HCG pregnancy test, or an FSH level < 30 mIU/mL during the post-treatment period. Long-term effects of bevacizumab products on fertility are unknown. Inform females of reproductive potential of the risk of ovarian failure prior to initiating Alymsys"
                            ,
                            "[see Adverse Reactions (6.1), Use in Specific Populations (8.3)]"
                            ,
                            "."
                            ,
                            ""
                            ,
                            ""
                            ,
                            "Alymsys is not indicated for use with anthracycline-based chemotherapy. The incidence of Grade ≥ 3 left ventricular dysfunction was 1% in patients receiving bevacizumab compared to 0.6% of patients receiving chemotherapy alone. Among patients who received prior anthracycline treatment, the rate of CHF was 4% for patients receiving bevacizumab with chemotherapy as compared to 0.6% for patients receiving chemotherapy alone."
                            ,
                            ""
                            ,
                            "In previously untreated patients with a hematological malignancy, the incidence of CHF and decline in left ventricular ejection fraction (LVEF) were increased in patients receiving bevacizumab with anthracycline-based chemotherapy compared to patients receiving placebo with the same chemotherapy regimen. The proportion of patients with a decline in LVEF from baseline of ≥ 20% or a decline from baseline of 10% to < 50%, was 10% in patients receiving bevacizumab with chemotherapy compared to 5% in patients receiving chemotherapy alone. Time to onset of left-ventricular dysfunction or CHF was 1 to 6 months after the first dose in at least 85% of the patients and was resolved in 62% of the patients who developed CHF in the bevacizumab arm compared to 82% in the placebo arm. Discontinue Alymsys in patients who develop CHF."
                            ,
                            ""
                            
            ],


            "adverseReactions": [
                
                            ""
                            ,
                            "The following clinically significant adverse reactions are described elsewhere in the labeling:"
                            ,
                            ""
                            ,
                            ""
                            ,
                            "Gastrointestinal Perforations and Fistulae"
                            ,
                            "[see Warnings and Precautions (5.1)]"
                            ,
                            "."
                            ,
                            ""
                            ,
                            "Surgery and Wound Healing Complications"
                            ,
                            "[see Warnings and Precautions (5.2)]"
                            ,
                            "."
                            ,
                            ""
                            ,
                            "Hemorrhage"
                            ,
                            "[see Warnings and Precautions (5.3)]"
                            ,
                            "."
                            ,
                            ""
                            ,
                            "Arterial Thromboembolic Events"
                            ,
                            "[see Warnings and Precautions (5.4)]"
                            ,
                            "."
                            ,
                            ""
                            ,
                            "Venous Thromboembolic Events"
                            ,
                            "[see Warnings and Precautions (5.5)]"
                            ,
                            "."
                            ,
                            ""
                            ,
                            "Hypertension"
                            ,
                            "[see Warnings and Precautions (5.6)]"
                            ,
                            "."
                            ,
                            ""
                            ,
                            "Posterior Reversible Encephalopathy Syndrome"
                            ,
                            "[see Warnings and Precautions (5.7)]"
                            ,
                            "."
                            ,
                            ""
                            ,
                            "Renal Injury and Proteinuria"
                            ,
                            "[see Warnings and Precautions (5.8)]"
                            ,
                            "."
                            ,
                            ""
                            ,
                            "Infusion-Related Reactions"
                            ,
                            "[see Warnings and Precautions (5.9)]"
                            ,
                            "."
                            ,
                            ""
                            ,
                            "Ovarian Failure"
                            ,
                            "[see Warnings and Precautions (5.11)]"
                            ,
                            "."
                            ,
                            ""
                            ,
                            "Congestive Heart Failure"
                            ,
                            "[see Warnings and Precautions (5.12)]"
                            ,
                            "."
                            ,
                            ""
                            ,
                            ""
                            
            ]
        }
    